Serum Selenium Level and 10-Year Survival after Melanoma.

Emilia Rogoża-Janiszewska,Bartłomiej Masojć,Róża Derkacz,Jan Lubiński,Magdalena Boer,Tadeusz Dębniak,Wojciech Marciniak,Helena Rudnicka,Cezary Cybulski,Anna Jakubowska,Piotr Baszuk,Karolina Malińska,Andrzej Kram,Magdalena Kiedrowicz,Tomasz Huzarski,Marcin Lener,Jacek Gronwald

doi:10.3390/biomedicines9080991

Emilia Rogoża-Janiszewska, Bartłomiej Masojć + Show 15 more

Open Access

https://doi.org/10.3390/biomedicines9080991

Copy DOI

Abstract

Melanoma is one of the most aggressive human malignancies. The determination of prognostic biomarkers is important for the early detection of recurrence and for the enrollment of the patients into different treatment regimens. Herein, we report the 10-year survival of 375 melanoma patients depending on their serum selenium levels. The study group was followed up from the date of melanoma diagnosis until death or 2020. Patients were assigned to one of four categories, in accordance with the increasing selenium level (I–IV quartiles). The subgroup with low selenium levels had a significant lower survival rate in relation to patients with high selenium levels, HR = 8.42; p = 0.005 and HR = 5.83; p = 0.02, for uni- and multivariable models, respectively. In the univariable analysis, we also confirmed the association between Breslow thickness, Clark classification and age at melanoma prognosis. In conclusion, a low serum selenium level was associated with an increased mortality rate in the 10 years following melanoma diagnosis. Future studies in other geographic regions with low soil selenium levels should be conducted to confirm our findings.

Highlights

Melanoma is one of the most aggressive human malignancies
Selenium is an essential component of several major metabolic pathways, including the antioxidant defense system and the immune system, and selenium is incorporated into 30 different selenoproteins [3,4,5]
We report the 10-year survival of our cohort of melanoma patients depending on their serum selenium levels

Summary

Introduction

Over 320,000 new cases were diagnosed globally in 2020, with 57,000 deaths. Observatory indicate that over the last decade, the incidence rates of melanoma have increased by nearly 50%, with deaths increasing by 32%. The American Cancer Society, based on information from the SEER database, maintained by the National Cancer Institute (NCI), estimates the 5-year survival rate to be. The determination of prognostic biomarkers is important for the early detection of recurrence and for the enrollment of the patients into different treatment regimens [2]. Selenium is an essential component of several major metabolic pathways, including the antioxidant defense system and the immune system, and selenium is incorporated into 30 different selenoproteins [3,4,5]

Methods

Discussion

Conclusion